Short Lecture "Anti-inflammatory potential of components of Cannabis sativa L. with relevance to multiple sclerosis pathogenesis"

Toll-like receptors (TLRs) are the sensors of pathogen associated molecules that trigger tailored innate immune signalling responses. TLRs have been implicated in many diseases, including neurodegenerative diseases such as multiple sclerosis (MS). Cannabis sativa L. (C. sativa) contains an array of plant-derived (phyto) cannabinoids, flavonoids and terpenes that continue to gain attention for their potential as novel therapeutics in many areas of biomedicine. In particular, the phytocannabinoids have shown efficacy in experimental autoimmune encephalomyelitis (EAE), the murine model of MS, and are in clinical development for the management of the symptoms of MS. A growing body of literature indicates that components of C. sativa may interact with TLR signalling events with relevance to neuroinflammatory disease processes. Data presented herein demonstrate that MS is associated with peripheral inflammation in immune cells from people with (pw)MS, when compared to immune cells from healthy volunteers. Original data from our laboratory will be presented demonstrating that two major phytocannabinoids, Δ9- tetrahydrocannabinol (THC) and cannabidiol (CBD), in addition to terpenes/flavonoids, are novel regulators of both viral and bacterial inflammatory signalling pathways controlled by TLRs in human immune cells associated with MS pathogenesis. This presentation will highlight TLR signalling as a mechanism to be investigated in the development of new cannabinoid-based therapeutics for the treatment of neuroinflammatory disorders such as MS.

 

MissingLinkText

Conflict of Interest

The author declares no conflict of interest.

Publikationsverlauf

Artikel online veröffentlicht:
16. November 2023